Western Wealth Management LLC Sells 53 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Western Wealth Management LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,280 shares of the company’s stock after selling 53 shares during the period. Western Wealth Management LLC’s holdings in IDEXX Laboratories were worth $1,266,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in IDXX. Panagora Asset Management Inc. boosted its stake in shares of IDEXX Laboratories by 50.3% during the 1st quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock worth $1,768,000 after acquiring an additional 1,081 shares in the last quarter. Raymond James Trust N.A. boosted its stake in shares of IDEXX Laboratories by 26.8% during the 1st quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock worth $888,000 after acquiring an additional 343 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of IDEXX Laboratories by 77.1% during the 1st quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock worth $2,010,000 after acquiring an additional 1,600 shares in the last quarter. Moors & Cabot Inc. boosted its stake in shares of IDEXX Laboratories by 3.0% during the 1st quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock worth $961,000 after acquiring an additional 52 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in shares of IDEXX Laboratories by 15.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock worth $543,000 after acquiring an additional 134 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on IDXX. The Goldman Sachs Group boosted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Barclays boosted their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $591.50.

Insider Transactions at IDEXX Laboratories

In other news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock valued at $24,871,960. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 0.3 %

IDEXX Laboratories stock opened at $476.35 on Friday. The business has a 50 day moving average price of $538.02 and a two-hundred day moving average price of $508.81. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The stock has a market cap of $39.56 billion, a price-to-earnings ratio of 47.30, a price-to-earnings-growth ratio of 3.68 and a beta of 1.26. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same quarter in the prior year, the firm posted $2.05 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.